Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses the toxicities that are associated with PARP inhibitors in ovarian cancer.
Videos
ALK-Translocated Non-Small Cell Lung Cancer With Bone Metastases
Recurrent Metastatic Gastrointestinal Stromal Tumor
High-Risk Primary Myelofibrosis
Hydroxyurea Resistant Polycythemia Vera
Treatment of BRAF Mutated Non-Small Cell Lung Cancer
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Tucatinib: Chemo-Sparing Maintenance for HER2+ Metastatic Breast Cancer
2
Phase 3 Data Highlight Orca-T’s Clinical Benefits in Heme Malignancies
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Emerging Data Push Antibody-Drug Conjugates Into Earlier Lines of Therapy in DLBCL
5